GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Bioscience Animal Health PCL (BKK:BIS) » Definitions » Debt-to-EBITDA

Bioscience Animal Health PCL (BKK:BIS) Debt-to-EBITDA : 0.06 (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Bioscience Animal Health PCL Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Bioscience Animal Health PCL's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ฿3 Mil. Bioscience Animal Health PCL's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ฿4 Mil. Bioscience Animal Health PCL's annualized EBITDA for the quarter that ended in Dec. 2023 was ฿110 Mil. Bioscience Animal Health PCL's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 0.06.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Bioscience Animal Health PCL's Debt-to-EBITDA or its related term are showing as below:

BKK:BIS' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.07   Med: 2.64   Max: 21.55
Current: 0.08

During the past 7 years, the highest Debt-to-EBITDA Ratio of Bioscience Animal Health PCL was 21.55. The lowest was 0.07. And the median was 2.64.

BKK:BIS's Debt-to-EBITDA is ranked better than
93.56% of 1429 companies
in the Consumer Packaged Goods industry
Industry Median: 2.13 vs BKK:BIS: 0.08

Bioscience Animal Health PCL Debt-to-EBITDA Historical Data

The historical data trend for Bioscience Animal Health PCL's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioscience Animal Health PCL Debt-to-EBITDA Chart

Bioscience Animal Health PCL Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial 2.14 2.64 2.74 0.07 0.08

Bioscience Animal Health PCL Quarterly Data
Dec17 Dec18 Dec19 Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.07 0.11 0.43 0.13 0.06

Competitive Comparison of Bioscience Animal Health PCL's Debt-to-EBITDA

For the Packaged Foods subindustry, Bioscience Animal Health PCL's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bioscience Animal Health PCL's Debt-to-EBITDA Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Bioscience Animal Health PCL's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Bioscience Animal Health PCL's Debt-to-EBITDA falls into.



Bioscience Animal Health PCL Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Bioscience Animal Health PCL's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(3.147 + 3.705) / 84.741
=0.08

Bioscience Animal Health PCL's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(3.147 + 3.705) / 110.236
=0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Bioscience Animal Health PCL  (BKK:BIS) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Bioscience Animal Health PCL Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Bioscience Animal Health PCL's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Bioscience Animal Health PCL (BKK:BIS) Business Description

Traded in Other Exchanges
N/A
Address
Bond Street Road, No. 479, 4th Floor, Muangthongthani, Bangphut, Pakkret, Nonthaburi, THA, 11120
Bioscience Animal Health PCL engaged in manufacture, import and distribution of pharmaceutical supplies, medical devices, equipment, and products for livestock and companion animals (pets). Geographically, the company generates revenue from Thailand.

Bioscience Animal Health PCL (BKK:BIS) Headlines